GeneDx Faces Class Action Lawsuit Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 19 2026
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx for violations of securities laws, urging those who purchased securities between April 16, 2025, and May 4, 2026, to contact the firm by August 3, 2026, to participate.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin and lowered earnings projections in its Q1 2026 financial results released on May 4, 2026, alongside a $31.3 million impairment related to Fabric Genomics, indicating a deterioration in the company's financial health.
- False Statement Allegations: The complaint alleges that GeneDx made false and misleading public statements throughout the class period, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, encouraging them to understand their rights, which underscores the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 65.620
Low
155.00
Averages
171.43
High
200.00
Current: 65.620
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx Holdings Corp. for violations of the Securities Exchange Act, concerning securities purchased between April 16, 2025, and May 4, 2026, with a deadline for contact set for August 3, 2026.
- Declining Financial Performance: GeneDx's Q1 2026 financial results revealed a drop in adjusted gross margin, lowered earnings projections, and a $31.3 million impairment related to Fabric Genomics, indicating that the company's public statements were false and misleading during the class period.
- Investor Losses: As the market learned the truth about GeneDx's financial situation, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to join the lawsuit to recover losses, highlighting serious deficiencies in the company's transparency and compliance.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email, emphasizing their rights and options before the class action is certified, ensuring they can effectively protect their interests.
See More
GeneDx Faces Class Action Over Misleading Acquisition Claims Amid 49% Stock Plunge
- Stock Plunge: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, raising serious investor concerns about the company's future profitability.
- Acquisition Controversy: The lawsuit alleges that GeneDx misled investors regarding the acquisition of Fabric Genomics, claiming it would enhance efficiency and profitability, while the actual results showed a $2.5 million revenue miss and impairment losses amounting to 94% of the acquisition cost.
- Performance Decline: GeneDx reported a tenfold increase in net loss compared to the previous year in Q1, with an annual recurring revenue (ARR) drop of about $200, indicating a significant adverse change in product mix, particularly with genome ARR being only half that of exome.
- Leadership Change: Following the stock collapse, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to the alleged failures that preceded the May downturn, particularly the disconnect between public projections and internal realities.
See More
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial barriers for participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability were known to the defendants, adversely affecting GeneDx's operations.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering billions for investors, underscoring its expertise and resource capabilities in handling such cases.
See More
GeneDx Faces Class Action Over Misleading Acquisition Claims
- Lawsuit Investigation: Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings, alleging executives misled investors regarding the Fabric Genomics acquisition, which led to a 49% stock drop on May 5, 2026.
- Severe Financial Losses: GeneDx reported a tenfold increase in net loss for Q1 2026 compared to the previous year, primarily due to a $31.2 million impairment charge related to Fabric Genomics, representing about 94% of the cash paid for the acquisition.
- Revenue Guidance Cut: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenues would be at least 20%, significantly lower than previous forecasts, indicating a major adverse shift in product mix.
- Leadership Change: Following the stock collapse, GeneDx appointed new President Mark Gardner, and Hagens Berman is investigating whether this leadership change is connected to prior failures, potentially impacting investor confidence.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against GeneDx Holdings, alleging violations of federal securities laws during the period from April 16, 2025, to May 4, 2026, seeking damages for all investors who purchased GeneDx securities during this timeframe.
- Allegations of Misrepresentation: The complaint claims that GeneDx made materially false and misleading statements throughout the class period, failing to disclose significant adverse facts about the company's business, operations, and prospects, which misled investors regarding its financial health.
- Margin Decline Risks: Specifically, the lawsuit alleges that GeneDx may have misled investors about the importance of Fabric Genomics, resulting in declining profit margins and that the average reimbursement rates were not as “durable” as previously disclosed, further impacting the company's financial performance.
- Investor Action Deadline: Investors have until August 3, 2026, to request to be appointed as lead plaintiff in the case to share in any potential recovery, with the law firm offering services on a contingency fee basis, thereby reducing the financial burden on investors.
See More
GeneDx Faces Class Action Lawsuit Risks
- Class Action Initiation: Robbins Geller law firm announced that purchasers of GeneDx Holdings Corp. common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, indicating significant investor concerns regarding the company's financial health.
- Deteriorating Financial Performance: GeneDx's Q1 2026 report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, directly reflecting a $31.3 million impairment loss from the acquisition of Fabric Genomics, highlighting substantial financial pressures on the company.
- Stock Price Plunge Impact: Following the May 4, 2026, earnings announcement, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also lead to increased shareholder participation in the lawsuit, exacerbating the company's legal risks.
- Legal Liability Risks: The class action lawsuit alleges violations of the Securities Exchange Act of 1934 by GeneDx and its executives, and if successful, could result in significant financial penalties for the company, impacting its future operations and market reputation while increasing governance and compliance pressures.
See More
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx Holdings Corp. for violations of the Securities Exchange Act, concerning securities purchased between April 16, 2025, and May 4, 2026, with a deadline for contact set for August 3, 2026.
- Declining Financial Performance: GeneDx's Q1 2026 financial results revealed a drop in adjusted gross margin, lowered earnings projections, and a $31.3 million impairment related to Fabric Genomics, indicating that the company's public statements were false and misleading during the class period.
- Investor Losses: As the market learned the truth about GeneDx's financial situation, investors suffered damages, prompting the Schall Law Firm to encourage affected investors to join the lawsuit to recover losses, highlighting serious deficiencies in the company's transparency and compliance.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email, emphasizing their rights and options before the class action is certified, ensuring they can effectively protect their interests.
See More
GeneDx Faces Class Action Over Misleading Acquisition Claims Amid 49% Stock Plunge
- Stock Plunge: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, raising serious investor concerns about the company's future profitability.
- Acquisition Controversy: The lawsuit alleges that GeneDx misled investors regarding the acquisition of Fabric Genomics, claiming it would enhance efficiency and profitability, while the actual results showed a $2.5 million revenue miss and impairment losses amounting to 94% of the acquisition cost.
- Performance Decline: GeneDx reported a tenfold increase in net loss compared to the previous year in Q1, with an annual recurring revenue (ARR) drop of about $200, indicating a significant adverse change in product mix, particularly with genome ARR being only half that of exome.
- Leadership Change: Following the stock collapse, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to the alleged failures that preceded the May downturn, particularly the disconnect between public projections and internal realities.
See More
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial barriers for participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability were known to the defendants, adversely affecting GeneDx's operations.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering billions for investors, underscoring its expertise and resource capabilities in handling such cases.
See More
GeneDx Faces Class Action Over Misleading Acquisition Claims
- Lawsuit Investigation: Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings, alleging executives misled investors regarding the Fabric Genomics acquisition, which led to a 49% stock drop on May 5, 2026.
- Severe Financial Losses: GeneDx reported a tenfold increase in net loss for Q1 2026 compared to the previous year, primarily due to a $31.2 million impairment charge related to Fabric Genomics, representing about 94% of the cash paid for the acquisition.
- Revenue Guidance Cut: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenues would be at least 20%, significantly lower than previous forecasts, indicating a major adverse shift in product mix.
- Leadership Change: Following the stock collapse, GeneDx appointed new President Mark Gardner, and Hagens Berman is investigating whether this leadership change is connected to prior failures, potentially impacting investor confidence.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against GeneDx Holdings, alleging violations of federal securities laws during the period from April 16, 2025, to May 4, 2026, seeking damages for all investors who purchased GeneDx securities during this timeframe.
- Allegations of Misrepresentation: The complaint claims that GeneDx made materially false and misleading statements throughout the class period, failing to disclose significant adverse facts about the company's business, operations, and prospects, which misled investors regarding its financial health.
- Margin Decline Risks: Specifically, the lawsuit alleges that GeneDx may have misled investors about the importance of Fabric Genomics, resulting in declining profit margins and that the average reimbursement rates were not as “durable” as previously disclosed, further impacting the company's financial performance.
- Investor Action Deadline: Investors have until August 3, 2026, to request to be appointed as lead plaintiff in the case to share in any potential recovery, with the law firm offering services on a contingency fee basis, thereby reducing the financial burden on investors.
See More
GeneDx Faces Class Action Lawsuit Risks
- Class Action Initiation: Robbins Geller law firm announced that purchasers of GeneDx Holdings Corp. common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, indicating significant investor concerns regarding the company's financial health.
- Deteriorating Financial Performance: GeneDx's Q1 2026 report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, directly reflecting a $31.3 million impairment loss from the acquisition of Fabric Genomics, highlighting substantial financial pressures on the company.
- Stock Price Plunge Impact: Following the May 4, 2026, earnings announcement, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also lead to increased shareholder participation in the lawsuit, exacerbating the company's legal risks.
- Legal Liability Risks: The class action lawsuit alleges violations of the Securities Exchange Act of 1934 by GeneDx and its executives, and if successful, could result in significant financial penalties for the company, impacting its future operations and market reputation while increasing governance and compliance pressures.
See More
